Nectar Laboratories Private Limited

Packaging Size	1*03 trips
Strength	150+100 mg
Composition	Nirmatrelvir and Ritonavir
Treatment	covid
Prescription/Non prescription	Prescription
Form	Tablet
Quantity	3000
Quantity Unit	Box
Also gives	ON BRAND NAME
Country of Origin	Made in India

Nirmatrelvir and Ritonavir The combination of nirmatrelvir and ritonavir is used to treat coronavirus disease 2019 (COVID-19 infection) caused by the SARS-CoV-2 virus ... disease that could result in hospitalization or death. Nirmatrelvir is in a class of medications called antivirals. ...

The dose of this medicine will be different for different patients. Follow your doctor''s orders or the directions on the label. The following information includes only the average doses of this medicine. If your dose is different, do not change it unless your doctor tells you to do so.

The amount of medicine that you take depends on the strength of the medicine. Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine.

• For oral dosage form (tablets):
  • For treatment of mild to moderate COVID-19:
    • Adults and children 12 years of age and older weighing 40 kilograms (kg) or more—300 milligrams (mg) (2 tablets) of nirmatrelvir and 100 mg (1 tablet) of ritonavir taken as a single dose 2 times a day for 5 days.
    • Children younger than 12 years of age or weighing less than 40 kg—Use and dose must be determined by your doctor.

Additional Information:

• Item Code: Z005
• Production Capacity: 50000/DAY
• Delivery Time: 15days
• Packaging Details: The American Society of Health-System Pharmacists, Inc. represents that this information about nirmatrelvir and ritonavir was formulated with a reasonable standard of care, and in conformity with professional standards in the field. Readers are cautioned that nirmatrelvir and ritonavir are not approved for treatment of coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2, but rather, are being investigated for and are currently available under, an FDA emergency use authorization (EUA) for the treatment of COVID-19 in certain adults and children 12 years of age and older. The American Society of Health-System Pharmacists, Inc. makes no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to the information, and specifically disclaims all such warranties. Readers of the information about nirmatrelvir and ritonavir are advised that ASHP is not responsible for the continued currency of the information, for any errors or omissions, and/or for any consequences arising from the use of this information. Readers are advised that decisions regarding drug therapy are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and the information contained in this information is provided for informational purposes only. The American Society of Health-System Pharmacists, Inc. does not endorse or recommend the use of any drug. This information about nirmatrelvir and ritonavir are not to be considered individual patient advice. Because of the changing nature of drug information, you are advised to consult with your physician or pharmacist about specific clinical use of any and all medications.